Literature DB >> 13485079

Some factors that influence utilization of antihemophilic activity during clotting.

G D PENICK.   

Abstract

Keywords:  BLOOD COAGULATION; PLASMA/effects

Mesh：

Year:  1957        PMID： 13485079     DOI： 10.3181/00379727-96-23454

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


× No keyword cloud information.
  5 in total

1.  Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.

Authors:  H A Cooper; F F Reisner; M Hall; R H Wagner
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

2.  "THROMBOCYTOPENIC SERUM": AN ARTIFICIAL FACTOR VIII-DEFICIENT REAGENT.

Authors:  E DAVIDSON; S TOMLIN
Journal:  J Clin Pathol       Date:  1964-03       Impact factor: 3.411

3.  A LABILE SERUM FACTOR CLOTTING DEFECT: ITS DEMONSTRATION BY THE THROMBOPLASTIN GENERATION TEST AND ITS CLINICAL SIGNIFICANCE.

Authors:  W E Connor; E D Warner; J R Carter
Journal:  J Clin Invest       Date:  1961-01       Impact factor: 14.808

4.  The value of animal models.

Authors:  T C Jones
Journal:  Am J Pathol       Date:  1980-12       Impact factor: 4.307

5.  Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor.

Authors:  T S Zimmerman; O D Ratnoff; A E Powell
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.